Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

Jan 11, 2021
|
Andrew P. Han

This story has been updated to include additional comments from Illumina CEO Francis deSouza and CMO Phil Febbo.

NEW YORK – Illumina is in the process of obtaining regulatory approval for a pan-cancer genomic profiling assay in the US and Europe, which will be central to several new partnerships with pharma and genetic testing companies.

The next-generation sequencing-based clinical assay is one of several announcements Illumina CEO Francis deSouza made today at the virtual JP Morgan Healthcare Conference.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Worries About Increased Deadliness

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

Merck Stops SARS-CoV-2 Vaccine Development

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

PLOS Papers on Rare Venous Thromboembolism Variant, Vector Mosquito LncRNAs, More

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
17
Featured Webinar

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Sponsored by
BioLegend

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. Infectious Disease Test Firm Talis Biomedical Files for IPO

  2. NeoGenomics to Boost Growth of Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

    Premium

  3. Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

    Premium

  4. Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

    Premium

  5. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.